| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT01438372 | IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD | PHASE2 | WITHDRAWN | Wayne State University | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Intravenous iron sucrose|DRUG: Oral ferrous… | Details |
| NCT02774057 | Trial of Captafer vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer|DRUG: Iron Sulfate | Details |
| NCT02760940 | Anemia in Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Federal University of Juiz de Fora | Anemia|Bowel Diseases, Inflammatory | DRUG: oral liposomal iron | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | None | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | None | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | PHASE3 | COMPLETED | Vifor Pharma | Inflammatory Bowel Disease|Anemia|Iron Deficiency… | DRUG: Ferric carboxymaltose|DRUG: Iron Sucrose | Details |
| NCT06120322 | Machine Learning Approach to Study the Interactions Between Environment and Intestinal Tissue Homeostasis in IBD | None | NOT_YET_RECRUITING | IRCCS San Raffaele | Diabetes Mellitus, Type 1|Ulcerative Colitis | OTHER: Environmental factor monitoring; collectio… | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | RECRUITING | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | None | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru Real World Effectiveness Study in Hospital Practice ( FRESH ) | None | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT01017614 | Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia | PHASE3 | COMPLETED | Pharmacosmos A/S | Inflammatory Bowel Disease | DRUG: Monofer; DRUG: Iron Sulphate | Details |
| NCT05176795 | Host-microbiota-environment Interactions | Not Available | RECRUITING | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis; Diabetes type1; In… | OTHER: Stool sample | Details |
| ChiCTR2500100314 | Analysis of iron-related indexes and disease association in patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Inflammatory bowel disease | IBD patients:None; | Details |
| DRKS00034606 | CEDATA GPGE Patient Registry - Registry for chronic inflammatory bowel diseases in children and adolescents - CEDATA | Not Available | Recruiting | Gesellschaft f Piatrische Gastroenterologie und Ernrung e. V. | Inflammatory Bowel Disease K50-K52;Noninfective … | Group 1: Health Care Data is entered into an onli… | Details |
| NCT02517151 | Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue | PHASE2 | UNKNOWN | Istituto Clinico Humanitas | Chronic Fatigue|Inflammatory Bowel Disease | DRUG: Ferric carboxymaltose|DRUG: Placebo | Details |
| ACTRN12624000016538 | Longitudinal study of diet, lifestyle and biomarker predictors of pouchitis | Not Available | Not Recruiting | Monash University | Inflammatory bowel disease;familial adenomatous p… | We will be following individuals with an ileoanal… | Details |
| ChiCTR2200066959 | Study on the effect of iron supplementation on the efficacy of anti-TNF-a monoclonal antibody in patients with IBD | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group :iron isomaltoside;Control gro… | Details |
| ChiCTR2200066056 | A comparative study of iron isomaltoside versus traditional iron supplements in patients with inflammatory bowel diseases and iron deficiency anemia | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group:iron isomaltoside;Control grou… | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Oral iron exacerbates colitis and influences the intestinal microbiome
PMID: 30308045
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Comment in Gut. 2019 Jan;68(1):4-5. OBJECTIVE: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved f…
Gut Microbiota and Iron: The Crucial Actors in Health and Disease
PMID: 30301142
Year: 2018
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Endoplasmic reticulum [ER] stress was shown to be pivotal in the pathogenesis of inflammatory bowel disease. Despite progress in inflamm…
The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clini…
PMID: 30267029
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Comment in Lancet. 2017 Apr 29;389(10080):1671-1672. BACKGROUND: The interleukin-23 pathway is implicated genetically and biologically in the p…
Effectiveness of oral iron supplementation in treatment of anemia associated wi…
PMID: 30264865
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Dirty environment for adult life: The bad, the good, the unknown
PMID: 30258886
Year: 2016
Relationship Type:
Association
Score: 6.3
Not found
Safety and efficacy of intravenous iron isomaltoside for correction of anaemia …
PMID: 30222479
Year: 2018
Relationship Type:
Treatment
Score: 6.3
The high cost of biological drugs for patients with inflammatory bowel disease (IBD) considerably impacts on health-care budgets. Since the patent o…
Reproducing the human mucosal environment ex vivo: inflammatory bowel disease a…
PMID: 30188406
Year: 2018
Relationship Type:
Treatment
Score: 6.3
After 20 years of successful targeting of pro-inflammatory cytokines for the treatment of IBD, an alternative therapeutic strategy has emerged, base…
Debate session: So what causes inflammatory bowel disease? It's all in the envi…
PMID: 30187567
Year: 2018
Relationship Type:
Association
Score: 6.3
Epidemiology of inflammatory bowel disease-nature versus nurture: Genes versus …
PMID: 30187564
Year: 2018
Relationship Type:
Association
Score: 6.3
Inflammatory bowel disease environmental risk factors versus genetics based on …
PMID: 30187554
Year: 2018
Relationship Type:
Association
Score: 6.3
The Environmental Sensor AHR Protects from Inflammatory Damage by Maintaining I…
PMID: 30119997
Year: 2018
Relationship Type:
Association
Score: 6.3
Comment in Clin Gastroenterol Hepatol. 2019 Feb;17(3):395-396. BACKGROUND & AIMS: We aimed to evaluate the association of the patient-reported …
Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficienc…
PMID: 29955835
Year: 2018
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: This study aimed to test fecal calprotectin (FC) as a screening tool to identify inflammatory bowel disease (IBD) among patients with juv…
Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Infl…
PMID: 29788224
Year: 2018
Relationship Type:
Treatment
Score: 6.3
OBJECTIVES: Although it has been recommended to perform sigmoidoscopy to screen for cytomegalovirus (CMV) reactivation in acute severe colitis, the …
Practical guidance for the management of iron deficiency in patients with infla…
PMID: 29760784
Year: 2018
Relationship Type:
Association
Score: 6.3
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic disease that is associated with inflammatory bowel disease (IBD) in appr…
Reticulocyte hemoglobin content (MCHr) in the assessment of iron deficient eryt…
PMID: 29759803
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Cross-sectional MRI is an attractive alternative to endoscopy for the objective assessment of patients with inflammatory bowel disease (IBD). Diffus…
Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Con…
PMID: 29744352
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Inflammatory bowel disease (IBD) is a group of chronic remittent or progressive inflammatory gastrointestinal tract diseases, accompanying impaired …
Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Dise…
PMID: 29669068
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Comment in Dig Dis Sci. 2017 Oct;62(10):2618-2620. BACKGROUND AND AIMS: Fecal microbiota transplantation (FMT) has recently been shown to be a …
The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowe…
PMID: 29669023
Year: 2018
Relationship Type:
Treatment
Score: 6.3
It is well known that smoking is the risk factor in the development and clinical course of Crohn s disease (CD), but on the other hand, smoking is a…
Inflammatory bowel disease and anemia: intravenous iron treatment
PMID: 29468908
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Not found
Oral versus intravenous iron therapy in patients with inflammatory bowel diseas…
PMID: 29440920
Year: 2018
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Infantile-onset inflammatory bowel disease (IBD) comprises rare and clinically severe disorders. We examined the phenotypes and genetic …